Production (Stage)
Amphastar Pharmaceuticals, Inc.
AMPH
$24.47
$0.271.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 725.71M | 712.81M | 681.49M | 644.52M | 610.85M |
| Total Other Revenue | 4.95M | 19.15M | 42.06M | 68.37M | 65.36M |
| Total Revenue | 730.66M | 731.97M | 723.55M | 712.89M | 676.21M |
| Cost of Revenue | 361.65M | 358.11M | 340.20M | 323.08M | 308.83M |
| Gross Profit | 369.01M | 373.86M | 383.35M | 389.81M | 367.38M |
| SG&A Expenses | 97.34M | 94.52M | 92.90M | 88.15M | 84.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 535.96M | 526.55M | 509.29M | 483.01M | 464.65M |
| Operating Income | 194.70M | 205.42M | 214.26M | 229.89M | 211.56M |
| Income Before Tax | 172.75M | 189.19M | 186.07M | 201.63M | 183.90M |
| Income Tax Expenses | 31.12M | 29.67M | 28.35M | 35.12M | 29.21M |
| Earnings from Continuing Operations | 141.63 | 159.52 | 157.72 | 166.52 | 154.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 141.63M | 159.52M | 157.72M | 166.52M | 154.69M |
| EBIT | 194.70M | 205.42M | 214.26M | 229.89M | 211.56M |
| EBITDA | 248.30M | 258.39M | 266.61M | 281.46M | 256.09M |
| EPS Basic | 2.93 | 3.29 | 3.26 | 3.44 | 3.20 |
| Normalized Basic EPS | 2.23 | 2.44 | 2.40 | 2.60 | 2.38 |
| EPS Diluted | 2.76 | 3.06 | 3.01 | 3.14 | 2.90 |
| Normalized Diluted EPS | 2.10 | 2.27 | 2.22 | 2.38 | 2.15 |
| Average Basic Shares Outstanding | 193.14M | 193.72M | 193.70M | 193.78M | 193.27M |
| Average Diluted Shares Outstanding | 205.11M | 208.23M | 209.94M | 211.99M | 213.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |